Page 1 | Search Results | ASH Clinical News | American Society of Hematology

Skip to Main Content

Advertisement intended for health care professionals

Close

ASH
ASH Clinical News
ASH Image Bank Open External Link
ASH News Daily
ASH-SAP
Blood Journals
Hematology
The Hematologist
International

header search

search input Search input auto suggest

filter your search

Search

Menu

About
Viewpoints
Education
Spotlight
News
Topic Compilations

Skip Nav Destination

Update search

Querybuilder input 1 Querybuilder input

Title
Author
Full Text
Abstract
Keyword
DOI

Querybuilder input 2 Querybuilder input

Title
Author
Full Text
Abstract
Keyword
DOI

Querybuilder input 3 Querybuilder input

Title
Author
Full Text
Abstract
Keyword
DOI

Querybuilder input 4 Querybuilder input

Title
Author
Full Text
Abstract
Keyword
DOI

Querybuilder input 5 Querybuilder input

Title
Author
Full Text
Abstract
Keyword
DOI

Querybuilder input 6 Querybuilder input

Title
Author
Full Text
Abstract
Keyword
DOI

NARROW

Publications

Filter by publications

ASH Clinical News (141)

Format

Filter by format

News (140)

Topics

Filter by topics

Chronic Leukemias (141)
On Location (42)
In the Literature (25)
From the Blood Journals (21)
Written in Blood (20)
Literature Scan (16)
Online Only (12)
ASH Annual Meeting (11)
January Supplement 2024 (11)
Lymphomas & Lymphoid Neoplasia (10)

Date

Filter by date

Date range

Single date

From

To

Apply

Availability

Availability

1-20 of 141

1

Sort by

Sort Order Select

News

Next-Gen BCL2 Inhibitor Sonrotoclax Shows Good Outcomes in Phase I Trial

Thomas R. Collins

Published: 2025

Abstract

December 2025

View News titled, Next-Gen BCL2 Inhibitor Sonrotoclax Shows Good Outcomes in Phase I Trial

News

Zanubrutinib, Obinutuzumab, Sonrotoclax Combo Shows Positive Outcomes for Treatment-Naïve CLL

Leah Lawrence

Published: 2025

Abstract

December 2025

View News titled, Zanubrutinib, Obinutuzumab, Sonrotoclax Combo Shows Positive Outcomes for Treatment-Naïve CLL

News

Head-To-Head Data Strong for Pirtobrutinib Over Ibrutinib

Thomas R. Collins

Published: 2025

Abstract

December 2025

View News titled, Head-To-Head Data Strong for Pirtobrutinib Over Ibrutinib

News

Lisaftoclax Achieves Objective Response Primary Endpoint in Phase II R/R CLL Trial

Anna Azvolinsky, PhD

Published: 2025

Abstract

December 2025

View News titled, Lisaftoclax Achieves Objective Response Primary Endpoint in Phase II R/R CLL Trial

News

Fixed-Duration Targeted Treatment as Effective as BTK Inhibitor Therapy for CLL

Lara C. Pullen, PhD

Published: 2025

View News titled, Fixed-Duration Targeted Treatment as Effective as BTK Inhibitor Therapy for CLL

News

Delayed Obinutuzumab Enhances Safety in First-Line Acalabrutinib Plus Venetoclax for CLL

Katie Robinson

Published: 2025

View News titled, Delayed Obinutuzumab Enhances Safety in First-Line Acalabrutinib Plus Venetoclax for CLL

News

BTK Degrader Shows Tolerable Safety, High Responses in Phase I Study of R/R CLL/SLL

Katie Robinson

Published: 2025

View News titled, BTK Degrader Shows Tolerable Safety, High Responses in Phase I Study of R/R CLL/SLL

News

CLL-Frail Trial Indicates Acalabrutinib Safe, Effective for Older, Frail Patients

Lara C. Pullen, PhD

Published: 2025

Abstract

December Supplement 2025

View News titled, CLL-Frail Trial Indicates Acalabrutinib Safe, Effective for Older, Frail Patients

News

Five-Year Follow-Up of SEQUOIA Shows Zanubrutinib Effective Against Treatment-Naïve CLL

Lara C. Pullen, PhD

Published: 2025

Abstract

December Supplement 2025

View News titled, Five-Year Follow-Up of SEQUOIA Shows Zanubrutinib Effective Against Treatment-Naïve CLL

News

MRD-Guided Ibrutinib-Venetoclax Therapy Reduces Toxicity While Preserving Long-Term Efficacy in R/R CLL

Pinky Sharma

Published: 2025

Abstract

December Supplement 2025

View News titled, MRD-Guided Ibrutinib-Venetoclax Therapy Reduces Toxicity While Preserving Long-Term Efficacy in R/R CLL

News

MURANO: 7-Year Results Support Durability, Retreatment Potential of Venetoclax-Rituximab in Relapsed CLL

Pinky Sharma

Published: 2025

Abstract

December Supplement 2025

View News titled, MURANO: 7-Year Results Support Durability, Retreatment Potential of Venetoclax-Rituximab in Relapsed CLL

News

Zanubrutinib Plus Venetoclax Effective as Treatment for Untreated CLL/SLL

Lara C. Pullen, PhD

Published: 2025

Abstract

December Supplement 2025

View News titled, Zanubrutinib Plus Venetoclax Effective as Treatment for Untreated CLL/SLL

News

Is Targeted Therapy for a Fixed Duration More Effective Than Chemoimmunotherapy in Untreated CLL?

Katie Robinson

Published: 2025

Abstract

December Supplement 2025

View News titled, Is Targeted Therapy for a Fixed Duration More Effective Than Chemoimmunotherapy in Untreated CLL?

News

Early Ibrutinib Delays Disease but Doesn’t Extend Life in Early CLL; Watchful Waiting Still Reigns

Pinky Sharma

Published: 2025

Abstract

December Supplement 2025

View News titled, Early Ibrutinib Delays Disease but Doesn’t Extend Life in Early CLL; Watchful Waiting Still Reigns

News

Study Shows Measurable Residual Disease Could Be Used as Guide to Treat Chronic Lymphocytic Leukemia

Lara C. Pullen, PhD

Published: 2025

Abstract

December Supplement 2025

View News titled, Study Shows Measurable Residual Disease Could Be Used as Guide to Treat Chronic Lymphocytic Leukemia

News

What Is the Best Treatment for Double-Refractory CLL?

Lara C. Pullen, PhD

Published: 2025

Abstract

December Supplement 2025

View News titled, What Is the Best Treatment for Double-Refractory CLL?

News

Immunoglobulin Replacement Therapy Not Associated With Reduced Risk of Infection-Related Hospitalizations Among Patients with CLL

Anna Azvolinsky, PhD

Published: 2025

Abstract

November 2025

View News titled, Immunoglobulin Replacement Therapy Not Associated With Reduced Risk of Infection-Related Hospitalizations Among Patients with CLL

News

Individualized Therapy Associated With Greater Rates of Undetectable MRD, Extended PFS in CLL

Khylia Marshall

Published: 2025

Abstract

September 2025

View News titled, Individualized Therapy Associated With Greater Rates of Undetectable MRD, Extended PFS in CLL

News

Five-Year Results of SEQUOIA Trial Show Maintenance of Benefit for Patients With Del(17p) Treatment-Naïve CLL Treated With Zanubrutinib

Anna Azvolinsky, PhD

Published: 2025

Abstract

July 2025

View News titled, Five-Year Results of SEQUOIA Trial Show Maintenance of Benefit for Patients With Del(17p) Treatment-Naïve CLL Treated With Zanubrutinib

News

Patients With CMML Show Durable Response to Lenzilumab, Azacitidine Combo

Leah Lawrence

Published: 2025

Abstract

July 2025

View News titled, Patients With CMML Show Durable Response to Lenzilumab, Azacitidine Combo

1

About ASH Clinical News
Advertising
Subscribe

Contact Us

American Society of Hematology
2021 L Street NW, Suite 900
Washington, DC 20036
TEL +1 202-776-0544
FAX +1 202-776-0545

ASH Publications

Blood
Blood Advances
Blood Global Hematology
Blood Immunology & Cellular Therapy
Blood Neoplasia
Blood Red Cells & Iron
Blood Vessels, Thrombosis & Hemostasis
Hematology, ASH Education Program
ASH Clinical News
ASH-SAP
The Hematologist

American Society of Hematology

ASH Home
ASH Image Bank
ASH Store

Advocacy
Education
Meetings
Research

Copyright 2025 by American Society of Hematology

Cookie Settings
Privacy Policy
Cookie Policy
Terms of Use
Contact Us

This Feature Is Available To Subscribers Only

Sign In or Create an Account

Advertisement intended for health care professionals